Certificates of Supplementary Protection (CSP) and Applications

Register of Certificates of Supplementary Protection and Applications

(PDF format, 150 KB, 3 pages)

Certificates of Supplementary Protection and Applications - Human Use
Certificate of Supplementary Protection (CSP) and/or Application Number Medicinal Ingredient(s) New Drug Submission (NDS) Number Patent Number Patent Expiry Date
yyyy-mm-dd
Application Status CSP Term Begins
yyyy-mm-dd
CSP Term Ends
yyyy-mm-dd
900027 apalutamide 211942 2875767 2033-06-04 Pending    
900026 baricitinib 193687 2718271 2029-03-10 Pending    
900012 benralizumab 204008 2685222 2028-05-14 Issued 2028-05-15 2030-05-14
900028 bictegravir sodium / emtricitabine / tenofovir alafenamide hemifumarate 203718 2416757 2021-07-20 Pending    
900020 brigatinib 210369 2723961 2029-05-21 Pending    
900015 brodalumab 195317 2663537 2027-10-01 Issued 2027-10-02 2029-10-01
900022 cenegermin 218145 2346257 2019-10-11 Pending    
900011 coagulation factor IX (recombinant), pegylated 201114 2462930 2022-10-09 Refused    
900019 crisaborole 206906 2597982 2026-02-16 Issued 2026-02-17 2028-02-16
900017 darunavir ethanolate / cobicistat / emtricitabine / tenofovir alafenamide hemifumarate 199705 2678907 2028-02-22 Issued 2028-02-23 2030-02-22
900021

dolutegravir ( dolutegravir sodium) / rilpivirine (rilpivirine hydrochloride)

206402 2606282 2026-04-28 Pending    
900004 dupilumab 201285 2737044 2029-10-27 Issued 2029-10-28 2031-10-27
900010 durvalumab 202953 2778714 2030-11-24 Issued 2030-11-25 2032-11-04
900024

emicizumab

212635 2817964 2031-11-17 Pending    
900025 erenumab 208607 2746858 2029-12-18 Pending    
900018 ertugliflozin 204724 2733795 2029-08-17 Issued 2029-08-18 2031-08-17
900001 glecaprevir / pibrentasvir 202233 2807847 2031-10-12 Refused    
900014 glycopyrronium (as bromide) / formoterol fumarate dihydrate 201306 2763936 2030-05-28 Pending    
900003 guselkumab 200590 2635692 2026-12-28 Issued 2026-12-29 2028-12-28
900023

insulin glargine / lixisenatide

207006 2740685 2029-10-09 Pending    
900007 letermovir 204165 2524069 2024-04-17 Issued 2024-04-18 2026-04-17
900009 lifitegrast 199810 2609053 2026-05-17 Issued 2026-05-18 2028-05-17
900002 neisseria meningitidis grp B recombinant lipoprotein 2086 subfamily A / neisseria meningitidis grp B recombinant lipoprotein 2086 subfamily B 195550 2463476 2022-10-11 Issued 2022-10-12 2024-10-11
900008 olaratumab 203478 2680945 2026-06-19 Issued 2026-06-20 2028-06-19
900016 ribociclib (ribociclib succinate) 203884 2734802 2029-08-20 Issued 2029-08-21 2031-08-20
900005 semaglutide 202059 2601784 2026-03-20 Issued 2026-03-21 2028-03-20
900006 varicella-zoster virus glycoprotein E (gE) 200244 2600905 2026-03-01 Refused    
Certificates of Supplementary Protection and Applications - Veterinary Use
Certificate of Supplementary Protection (CSP) and/or Application Number Medicinal Ingredient(s) New Drug Submission (NDS) Number Patent Number Patent Expiry Date
yyyy-mm-dd
Application Status CSP Term Begins
yyyy-mm-dd
CSP Term Ends
yyyy-mm-dd
900013 lotilaner 193712 2747354 2029-12-17 Issued 2029-12-18 2031-12-17

Background

The Register of Certificates of Supplementary Protection (CSP) and Applications is maintained pursuant to the Certificate of Supplementary Protection Regulations and the Patent Act. The register includes information from CSPs and CSP applications. Under the subsection 115(1) of the Patent Act, the issuance of a CSP grants the certificate's holder and their legal representatives the same legal rights, privileges and liberties that are granted by the patent set out in the certificate, but only with respect to the making, constructing, using and selling of any drug that contains the medicinal ingredient, or combination of medicinal ingredients.

The format of the register is an electronic table. The register lists, in alphabetical order, the medicinal ingredient(s) in the CSPs and CSP applications.

Information regarding applications that are refused, declared invalid or void, expired or withdrawn will be removed from the register.

Information regarding the patent set out in the CSP or CSP application is available at the Canadian Intellectual Property Office.

For comments or questions, or to obtain a copy of a CSP or CSP application details, please contact the Office of Patented Medicines and Liaison by email at hc.opml-bmbl.sc@canada.ca or by telephone at 613-941-7281.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: